The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells

Soeun Park's research works Korea University, Seoul (KU) and other places

NCT-58 (CAS Number: 2411429-33-7)

Enniatin A inhibits the chaperone Hsp90 and unleashes the immune system against triple-negative breast cancer - ScienceDirect

Cells, Free Full-Text

Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth

HER2-positive MedChemExpress (MCE) Life Science Reagents

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Cancers, Free Full-Text

Design, synthesis, and biological evalution of bifunctional inhibitors against Hsp90-HDAC6 interplay - ScienceDirect

PDF) A novel HSP90 inhibitor targeting the C-terminal domain attenuates trastuzumab resistance in HER2-positive breast cancer

Effect of trastuzumab on tumor growth of HER2-overexpressing

Pan- and isoform-specific inhibition of Hsp90: Design strategy and recent advances - ScienceDirect

The C-terminal HSP90 inhibitor NCT-58 kills trastuzumab-resistant breast cancer stem-like cells

Following the design path of isoform-selective Hsp90 inhibitors: Small differences, great opportunities - ScienceDirect